Severe Community-Acquired Pneumonia due to Acinetobacter baumannii in North America: Case Report and Review of the Literature

David P. Serota, Emory School of Medicine
Mary Sexton, Emory University
Colleen Kraft, Emory University
Federico Palacio Bedoya, Emory University
Federico Palacio, Emory School of Medicine

Journal Title: Open Forum Infectious Diseases
Volume: Volume 5, Number 3
Publisher: Oxford University Press (OUP) | 2018-03, Pages ofy044-ofy044
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/ofid/ofy044
Permanent URL: https://pid.emory.edu/ark:/25593/s8qgf

Final published version: http://dx.doi.org/10.1093/ofid/ofy044

Copyright information:
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed June 9, 2018 9:10 AM EDT
Severe Community-Acquired Pneumonia due to *Acinetobacter baumannii* in North America: Case Report and Review of the Literature

David P. Serota,1 Mary Elizabeth Sexton,1 Colleen S. Kraft,1,2 and Federico Palacio1

1Division of Infectious Diseases, Department of Medicine, and 2Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia

*Acinetobacter baumannii* is a rare but emerging cause of fulminant community-acquired pneumonia (CAP-AB). We describe a patient from a rural area who developed acute respiratory distress syndrome and septic shock. We describe risk factors and characteristics of this syndrome and review published cases of CAP-AB from North America.

**Keywords.** *Acinetobacter baumannii*; community-acquired pneumonia.

**CASE PRESENTATION**

A 41-year-old man with severe alcohol use disorder was admitted to a hospital in Alabama in January with 2 days of productive cough, shortness of breath, and fever. He presented with septic shock, hypoxic respiratory failure, and bilateral pulmonary infiltrates (Figure 1). Laboratory results were notable for neutropenia (absolute neutrophil count 450 cells/mcL), thrombocytopenia (58 000 cells/mcL), and acute kidney injury (creatinine 1.9 mg/dl). He had a history of alcohol use disorder with prior alcohol withdrawal seizures. His level of recent alcohol consumption was unknown, but he did not have evidence of alcohol withdrawal during the hospitalization. He lived with his father in rural Alabama and was unemployed. He smoked approximately 5 cigarettes per day and did not use illicit drugs. He had no travel outside the eastern United States, no recent health care exposures, and no sick contacts.

He was started on vancomycin, piperacillin-tazobactam, levofloxacin, and oseltamivir. Hypoxemia progressed rapidly, and within the first 24 hours of hospitalization he was intubated with high ventilatory support requirements (FiO2 of 100% and positive-end expiratory pressure of 18 cm of water) despite paralysis with cisatracurium. Blood cultures from admission grew Gram-negative bacilli in both sets in the aerobic bottles after 12 hours of incubation. The organism was identified as *Acinetobacter baumannii* by matrix-assisted laser desorption ionization time of flight mass spectroscopy (MALDI-TOF). Drug resistance testing, performed by an automated biochemical testing system (MicroScan Walkaway, Beckman Coulter, Inc. Brea, CA), showed sensitivity to all antimicrobials tested, including ceftazidime, levofloxacin, ampicillin-sulbactam, and meropenem.

The patient was transferred to our institution for initiation of venovenous extracorporeal membrane oxygenation (ECMO). On arrival, he required norepinephrine and vasopressin for blood pressure support, and antimicrobials were changed to intravenous meropenem and levofloxacin. Bronchoalveolar lavage showed many Gram-negative coccobacilli on Gram stain with growth of *A. baumannii* in culture with similar sensitivity to the previously obtained blood cultures. Antimicrobials were changed to intravenous ampicillin-sulbactam and levofloxacin, and he completed a 14-day course of therapy. His ECMO was discontinued after 9 days of therapy. He continued to require ventilatory support, necessitating tracheostomy, and was transferred to a subacute rehabilitation facility with eventual recovery.

**DISCUSSION**

*Acinetobacter baumannii* is an aerobic, oxidase-negative nonfermenting Gram-negative coccobacillus most often associated
with hospital-acquired infections, particularly ventilator-associated pneumonia (VAP). Hospital-acquired *A. baumannii* is associated with extended length of hospital stay and high mortality [1]. However, during the last 25 years, there has been a growing body of literature describing severe community-acquired pneumonia due to *A. baumannii* (CAP-AB) in patients without health care exposure or classic risk factors for this organism [2]. The majority of these cases come from Northern Australia and Asia, including Thailand, China, Taiwan, and are more common in tropical and subtropical areas during the summer months. Throat and skin carriage of *Acinetobacter* has been identified in areas of endemicity, and soil, livestock, and other animals have also been shown to serve as community reservoirs for *Acinetobacter* [3]. Based on pulse-field gel electrophoresis analyses, community-acquired isolates represent a distinct lineage from health care–associated *Acinetobacter* infections and often do not harbor the same resistance mechanisms [3]. Although less drug-resistant than hospital-acquired *A. baumannii* bacteremia, community-acquired infection has been associated with increased mortality (odds ratio, 5.72; 95% confidence interval, 1.02–32.00) [4].

Epidemiologic studies have linked the syndrome of severe CAP-AB with alcohol use disorder and recent alcohol binges prior to symptom onset [5]. Animal studies have shown that alcohol has wide-ranging effects on the innate immune system in relation to pulmonary *Acinetobacter* infection [6–8]. Gandhi et al. compared ethanol-exposed mice with unexposed mice after pulmonary inoculation of *Acinetobacter* [6]. They showed that ethanol-exposed mice demonstrated decreased neutrophil-mediated phagocytosis, increased lung inflammation, and higher mortality. Asplund et al. similarly showed decreased alveolar macrophage phagocytosis of *Acinetobacter* in the presence of alcohol [7]. Other significant risk factors include tobacco use, chronic pulmonary disease, and diabetes mellitus [2]. Onset of symptoms is typically rapid, with fulminant disease developing over 48–72 hours. Bilateral infiltrates, ARDS,

**Table 1. Summary of North American Cases of Community-Acquired Pneumonia due to *Acinetobacter baumannii***

<table>
<thead>
<tr>
<th>Year (Reference)</th>
<th>Location</th>
<th>Age</th>
<th>Sex</th>
<th>Risk Factors</th>
<th>Mech. Vent.</th>
<th>Site of Positive Cultures</th>
<th>Final Antibiotics Used</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1959 [10]</td>
<td>Chicago, IL</td>
<td>50</td>
<td>M</td>
<td>None</td>
<td>No</td>
<td>Blood and sputum</td>
<td>Chloramphenicol and oxytetracycline</td>
<td>Survived</td>
</tr>
<tr>
<td>1973 [12]</td>
<td>Baltimore, MD</td>
<td>69</td>
<td>M</td>
<td>CKD</td>
<td>Yes</td>
<td>Tracheal aspirate and pleural fluid</td>
<td>Tetracycline</td>
<td>Died</td>
</tr>
<tr>
<td>1976 [13]</td>
<td>Houston, TX</td>
<td>50</td>
<td>M</td>
<td>Alcohol, tobacco</td>
<td>Yes</td>
<td>Blood and tracheal aspirate</td>
<td>Gentamicin and carbenicillin</td>
<td>Survived</td>
</tr>
<tr>
<td>1979 [15]</td>
<td>Dallas, TX</td>
<td>58</td>
<td>M</td>
<td>Alcohol, asthma</td>
<td>?</td>
<td>Blood</td>
<td>Clindamycin and gentamicin</td>
<td>Died</td>
</tr>
<tr>
<td>1981 [16]</td>
<td>Hartford, CT</td>
<td>54</td>
<td>M</td>
<td>Alcohol, pancreatitis, hepatitis</td>
<td>Yes</td>
<td>Blood and tracheal aspirate</td>
<td>Gentamicin, gentamicin, and carbenicillin</td>
<td>Survived</td>
</tr>
<tr>
<td>1993 [18]</td>
<td>Chicago, IL</td>
<td>74</td>
<td>F</td>
<td>None</td>
<td>Yes</td>
<td>Blood</td>
<td>Gentamicin, ticarcillin-clavulanate, and erythromycin</td>
<td>Survived</td>
</tr>
<tr>
<td>1999 [19]</td>
<td>Tampa, FL</td>
<td>80</td>
<td>M</td>
<td>None</td>
<td>No</td>
<td>BAL</td>
<td>Trimethoprim-sulfamethoxazole</td>
<td>Survived</td>
</tr>
<tr>
<td>2017 [20]</td>
<td>Atlanta, GA</td>
<td>41</td>
<td>M</td>
<td>Alcohol</td>
<td>Yes</td>
<td>Blood and BAL</td>
<td>Ampicillin-sulbactam and levofloxacin</td>
<td>Survived</td>
</tr>
</tbody>
</table>

Abbreviations: ?, unreported data; BAL, bronchoalveolar lavage; CKD, chronic kidney disease; f, female; M, male.

**Box 1. Characteristics Of The Cap-Ab Syndrome**

- Rapid onset of symptoms with fulminant disease
- Alcohol use disorder, especially binge episode
- Leukopenia
- Middle-aged men
- Tobacco use
- Right > left lung infiltrates
- Warm moist environments
leukopenia, and bacteremia are all common. A right-lung pre-
dominance has been noted, which likely implicates an element of aspiration to the pathogenesis of this condition [9]. Taking into account characteristics from multiple series, a distinct clinical syndrome of CAP-AB emerges (Box 1).

To date, 19 cases of CAP-AB have been reported in North America (Table 1). While most cases of CAP-AB in Southeast Asia and Australia have been reported since the late 1990s, most North American cases were published between 1959 and 1981, with the most recent report from 1999 [10–19]. Overall, these North American cases conform to the typical presentation of the “CAP-AB syndrome” described outside of North America. Most patients were middle-aged (median age, 54 years), male (15/19), and reported a history of alcohol use (10/19). All but two patients presented with a rapid-onset of illness with ≤3 days of symptoms and fulminant disease. Eleven of 15 patients with reported information on respiratory support required mechanical ventilation. Our patient was the only case with the use of ECMO for cardiopulmonary support. Mortality was high (42%), although many of the cases occurred prior to the advent of modern diagnostic and therapeutic advances, which is exemplified by the frequent use of aminoglycosides as definitive therapy (13/19 cases).

It is possible that CAP-AB in North America occurs more frequently but is underreported because identification of Acinetobacter is not noteworthy outside of the community-acquired context. It is also possible that climate plays a role in identification of only a small number of cases in the northern hemisphere, as the majority of cases have been identified in tropical locations [2]. Studies have demonstrated that even healthcare-associated cases may have some seasonal variation. For example, when surveillance data on Acinetobacter infections were collected at Yale–New Haven Hospital from 1990–1992, the incidence during the summer months was more than double the incidence during the remainder of the year [20]. The fact that our patient became critically ill during the winter is therefore unusual, although multiple cities in Alabama documented record high average temperatures throughout the year of this patient’s illness [21]. The etiology of this association of cases with warmer temperatures remains unknown and is a potential area for further study, especially as it suggests that climate change could ultimately influence disease prevalence.

CONCLUSION
This case is a representative example of the CAP-AB syndrome in a patient in the Southeast United States in 2017. While much focus is appropriate directed toward multidrug-resistant nosocomial Acinetobacter infections, we present this case to raise awareness of the presence of CAP-AB and document its contemporary existence outside of its typical area of endemicity. Previous reported cases in North America have been sporadic and infrequent since the 1950s, but globalization, climate change, and increasing prevalence of alcohol use disorder [22] could lead to emergence of this syndrome in the United States.

Acknowledgments
Financial support. This work is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR002378 and TL1TR002382, both D.P.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References